MedTrace Logo

S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma

NCT00107419 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2012-01-18

No results posted yet for this study

Summary

RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent and unresectable or metastatic chondrosarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

pemetrexed disodium

pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Warren A. Chow, MD · City of Hope Comprehensive Cancer Center

  • Ernest C. Borden, MD · The Cleveland Clinic

  • Vivien H.C. Bramwell, MB, BS, PhD, FRCP · Tom Baker Cancer Centre - Calgary

  • George D. Demetri, MD · Dana-Farber Cancer Institute

  • Margaret von Mehren, MD · Fox Chase Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-05-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00107419 on ClinicalTrials.gov